ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
Natural Capsules Ltd dispatched a corrigendum to its upcoming EGM notice, revising the issue price and quantity for the proposed preferential allotment of shares and warrants.
Natural Capsules Limited approved a revised preferential issue of 1,12,500 equity shares and 4,50,000 convertible warrants. The total aggregate fund raise is valued at Rs. 10.01 Crore.
NCL reported Q1FY27 revenue of ₹48.71 Cr (+8% Y-o-Y) with EBITDA at ₹1.12 Cr. Strategy focuses on scaling steroidal API volumes and HPMC line conversions to optimize capacity.
Natural Capsules Ltd reported revenue from operations of ₹48.7 Cr (+7.7% YoY) and a net loss of ₹5.7 Cr for Q1 FY27.
Natural Capsules Ltd reported Q4 FY26 revenue of ₹58.45cr (up 55% QoQ). Full-year FY26 revenue grew 11% to ₹187.20cr, though the company posted a net loss of ₹24.66cr.
Natural Capsules reports Q4FY26 revenue of ₹58.45 Cr (+30% Y-o-Y) while facing a PAT loss of ₹4.98 Cr. Strategy focuses on steroidal API scaling and HPMC capsule expansion.
Natural Capsules Ltd reported revenue from operations of ₹58.5 Cr (+30.0% YoY) and a net loss of ₹5 Cr for Q4 FY26.